



THERASPHERE™ Y-90 Glass Microspheres | **TARGET STUDY**

A global real-world retrospective study that confirms TheraSphere for HCC as safe and effective, demonstrating predictable clinical outcomes across a broad patient population in 8 countries.

Lam, M., Garin, E., Maccauro, M. et al. A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging (2022). <https://doi.org/10.1007/s00259-022-05774-0>

STUDY OBJECTIVE

Establish the relationships between:

- Normal tissue adsorbed dose (NTAD) and occurrence of grade 3 or higher hyperbilirubinemia
- Tumor absorbed dose (TAD) and Objective Response Rate (ORR)
- TAD and Overall Survival (OS)

STUDY DESIGN

Key Patient Characteristics


- Mainly Intermediate and Advanced HCC: 32.5% BCLC B and 54.5% BCLC C
- 7 cm median target lesion
- 33% PVT*

Dosimetry Approach

- Investigator review of patient chart and dosimetry calculation
- Retrospective dosimetry evaluation with multi-compartment approach using Simplicit⁹⁰Y™ personalized dosimetry software to determine TAD and NTAD

*TheraSphere not indicated for patients with PVT.

RESULTS




70.8% ORR*
for the target lesion (mRECIST)

61.7% ORR**
for all lesions (mRECIST)

20.3 months
median Overall Survival

*95% CI = 64.3 - 76.6%
**95% CI = 55.0 - 68.0%

TUMOR ABSORBED DOSE WAS PREDICTIVE OF RESPONSE^{1,2}



Responders had a

17% higher

mean tumor absorbed dose (225.5 Gy*) compared with non-responders (188.3 Gy**)

*95% CI = 201.0 - 253.0 Gy


**95% CI = 164.6 - 215.3 Gy; p=0.046

1. Total perfused tumor absorbed dose and best response (61.7%) according to mRECIST
2. Non-responders (defined as stable disease, progressive disease, or non-evaluable) are not represented in the graph

TUMOR ABSORBED DOSE WAS PREDICTIVE OF OVERALL SURVIVAL

KAPLAN-MEIER OVERALL SURVIVAL CURVES

Total Perfused Tumor Absorbed Dose by Subgroups




Median Overall Survival

>300 Gy - 36.7 months
(95% CI: 20.2 - 43.9 months)

>200 - <300 Gy - 25.1 months
(95% CI: 14.5 - 32.9 months)

<200 Gy - 16.1 months
(95% CI: 11.3 - 19.4 months)

LOW RATE OF ≥ GRADE 3 HYPERBILIRUBINEMIA CONFIRMS SAFETY OF TARGET STUDY



Only 4.8% of patients (10/209) experienced ≥ Grade 3 hyperbilirubinemia in the absence of disease progression

Regarding the low rate of event, no correlation could be established with normal tissue absorbed dose (p=0.6 for NTAD)

THERASPHERE™ Y-90 Glass Microspheres | TARGET STUDY

PATIENT CHARACTERISTICS

TREATED POPULATION

Parameter	(N=209) N (%)
Median age (range), years	66.0 (27-87)
Gender, male	166 (79.4%)
ECOG Status	
0	135 (64.6%)
1	67 (32.1%)
≥2	7 (3.4%)
BCLC Status	
A	27 (12.9%)
B	68 (32.5%)
C	114 (54.5%)
Child-Pugh Status	
A (5-6)	187 (89.5%)
B 7	22 (10.5%)
Unilobar or Bilobar Disease	
Unilobar	148 (70.8%)
Bilobar	61 (29.2%)

PATIENT CHARACTERISTICS

TREATED POPULATION

Parameter	(N=209) N (%)
With PVT	69 (33.0%)
Location of Target Lesion	
Left Lobe	30 (14.4%)
Right Lobe	179 (85.6%)
Target Lesion Longest Diameter (RECIST 1.1)	
≥3 to <5 cm	41 (19.6%)
≥5 to <8 cm	72 (34.4%)
≥8 cm	96 (45.9%)
Total Number of Lesions (target and non-target)	
1	145 (69.4%)
2	45 (21.5%)
3	14 (6.7%)
4-10	5 (2.4%)

The TARGET study provides real-world data confirming a significant association between TAD and objective response and between TAD and OS in HCC patients treated with Y-90 glass microspheres.

STUDY TAKEAWAYS

Dose Matters

Deliver the highest dose to the tumor that is safely possible to maximize patient response and improve survival

Predictability

Predictable results across 8 countries using multi-compartmental dosimetry using SimpliCt®⁹⁰Y personalized dosimetry software

Consistency

Like the LEGACY study and DOSISPHERE-01 trial results, the TARGET study reinforces the association between higher tumor absorbed dose and clinical outcomes

THERASPHERE™ YTTRIUM-90 GLASS MICROSPHERES

INDICATION FOR USE: TheraSphere is indicated for use as selective internal radiation therapy (SIRT) for local tumor control of solitary tumors (1-8 cm in diameter), in patients with unresectable hepatocellular carcinoma (HCC), Child-Pugh Score A cirrhosis, well-compensated liver function, no macrovascular invasion, and good performance status. **CONTRAINDICATIONS:** TheraSphere is contraindicated in patients: whose Tc-99m macroaggregated albumin (MAA) hepatic arterial perfusion scintigraphy shows any deposition to the gastrointestinal tract that may not be corrected by angiographic techniques • who show shunting of blood to the lungs that could result in delivery of greater than 16.5 mCi (0.61 GBq) of Y-90 to the lungs. Radiation pneumonitis has been seen rarely in patients receiving doses to the lungs greater than 30 Gy in a single treatment • in whom hepatic artery catheterization is contraindicated, such as patients with vascular abnormalities or bleeding diathesis • who have pulmonary insufficiency (conventionally defined by an arterial oxygen pressure (PaO2) of < 60 mmHg, or oxygen saturation (SaO2) of < 90%) or severe liver dysfunction, including hepatic encephalopathy, clinically evident ascites or treatment with diuretics for ascites • with portal vein thrombosis (PVT) Type 4 involvement and lack of Tc-99m MAA deposition on the PVT seen on the Tc-99m MAA imaging with >70% tumor replacement in the liver • with comorbidities or poor overall health (e.g., ECOG performance status rating > 2) which may make the patient a poor candidate for locoregional radiation treatment • who are pregnant. **WARNINGS:** The following pre-treatment, high-risk factors (disease characteristics) have been associated with serious adverse events deemed possibly related to use of the device: infiltrative tumor type • tumor nodules too numerous to count • AST or ALT > 5 times ULN • bilirubin > 2 mg/dL • tumor volume > 50% combined with albumin < 3 g/dL. Keep the TheraSphere dose vial upright and stored in its lead pot before and during patient treatment, except as required for radiation measurement. Do not open the dose vial acrylic shield prior to patient treatment. Post-treatment, waste materials require caution to prevent contamination and beta shielding due to residual glass microspheres. **PRECAUTIONS: GENERAL PRECAUTIONS:** As in any intra-arterial procedure, aseptic technique should be practiced, and care should be taken to ensure minimum patient anesthesia exposure extraneous to therapeutic objective. • Consideration of patient comorbidities should be used when determining the type and volume of fluid to infuse via catheter to avoid electrolyte imbalance, fluid shift, and hypoglycemia. • It is important to avoid any aggressive arterial procedure that may lead to arterial spasm that impairs TheraSphere distribution into the perfused liver target volume which may lead to underdosage or non-target deposition of TheraSphere. **PRECAUTION IN PATIENTS WITH IMPAIRED LIVER FUNCTION:** No efficacy or safety data from the LEGACY study are available to support the use of the device in patients with Child-Pugh score B or C cirrhosis. **PRECAUTION IN VULNERABLE PATIENTS:** No effectiveness or safety data are available to support the use of the device in children or breast-feeding women. **ENDOCRINE DISRUPTION, CARCINOGENICITY, MUTAGENICITY, TOXICITY TO REPRODUCTION:** Ideally the use of this radioactive device in women of childbearing capability should be performed during the first few (approximately 10) days following the onset of menses. **RADIATION SAFETY:** Radioactive products should be used only by healthcare professionals who are qualified by specific training in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate government agency authorized to license the use of radionuclides. • As in the use of any radioactive material, ensure minimum radiation exposure to the patient extraneous to the therapeutic objective, and to minimize radiation exposure to workers and others in contact with the patient. **RELEASE AND POST-TREATMENT PRECAUTIONS:** Post-treatment patient care: use universal precautions for body fluid contact. Trace Y-90 may be detectable in blood and urine; handle with gloves and dispose as normal body fluids. The radiation field is expected to be less than 1 mrem/h (10 µSv/h) at 3 ft (1 m) from the patient's abdomen. Supplemental shielding and segregation of the patient are not required to maintain exposure to others below regulated limits. • Release instructions: The patient should follow good hygiene (e.g., proper hand washing). Caregivers, family, and others do not require restrictions on patient contact; however, they can minimize their radiation exposure by avoiding prolonged time (>12 hours per day) within 1 ft (0.3 m) of the patient's abdomen for the first week post therapy. Patients should be advised that radiation emitted from the patient may be detectable at security screening (e.g., international travel). • Special precautions post-administration: If the patient requires hospitalization, surgery, medical assessment or treatment regarding any part of their thorax or abdomen within first 2 weeks of treatment, the patient should advise the hospital and treating physician of the Y-90 TheraSphere implant. The physician should consult their radiation safety staff for handling and disposal of liver tissue. • Special liver tissue handling: Special liver tissue handling may be required for post-treatment surgery, explant, or transplant since the glass microspheres remain permanently implanted in the liver tissue. Disclosure of the treatment will be required if cremation is considered. **POTENTIAL ADVERSE EVENTS:** The use of this product leads to irradiation of both tumors and normal liver tissue. As a result, patients with compromised liver function may be at greater risk of liver function impairment and hence could experience complications. Clinical side effects usually occur within the first 4 to 6 weeks after treatment. Based on clinical trial data, literature reviews and post-market surveillance, adverse events potentially associated with treatment using Y-90 microspheres, including TheraSphere, may include the following: Allergic reaction • Altered liver function, acute or chronic • Anorexia • Anxiety • Ascites • Bile Duct injury • Bleeding/hemorrhage • Chills / rigors • Cholecystitis (inflammatory or infectious) • Colitis • Death • Dehydration • Diarrhea • Dizziness • Dyspnea • Edema (any location) • Electrolyte abnormalities • Elevated BUN/creatinine • Fall • Fatigue • Fever • Gastrointestinal bleeding / hemorrhage • Gastrointestinal ulcer or ulceration • Hepatic encephalopathy • Hepatorenal failure • Hiccups • Hypertension • Hypotension • Infection (any location) • Liver failure, acute or chronic • Lymphopenia • Malaise • Mood alteration • Muscle weakness • Nausea • Neutropenia • Pain (any location) • Pancreatitis • Platelet count abnormalities • Pleural effusion • Portal hypertension • Pre-existing chronic liver disease decompensation • Pulmonary edema • Pulmonary fibrosis • Radiation hepatitis • Radiation induced disease, acute • Radio Embolization Induced Liver Disease (REILD) • Sepsis • Supraventricular arrhythmia • Thrombosis (arterial or venous) • Tumor inflammation (including tumor edema) • Tumor-lysis syndrome • Vomiting • Weight loss. Complications related to the administration procedure itself may include: Allergic reaction: Arterial injury including vessel dissection • Aspiration pneumonia • Bloating/bleeding/hematoma at site • Constipation/abdominal distension • Fatigue • Flushing • Infection • Nausea • Nerve damage. **CAUTION:** Federal (USA) law restricts this device to sale by or on order of a physician. **PI-992004-AA. NOTE:** Dose to the liver does not exceed 150 Gy. TheraSphere is a registered trademark of Theragenics Corporation used under license by Boston Scientific Medical Device Limited, a wholly owned indirect subsidiary of Boston Scientific Corporation. SimpliCt®⁹⁰Y is a registered trademark of Boston Scientific Medical Device Limited, a wholly owned indirect subsidiary of Boston Scientific Corporation, and is used under license by Mirada Medical Limited. All trademarks are the property of their respective owners.

Boston Scientific
Advancing science for life™

Peripheral Interventions
300 Boston Scientific Way
Marlborough, MA 01752-1234
www.bostonscientific.com

To order product or for more information
contact customer service at 1.888.272.1001.

© 2025 Boston Scientific Corporation
or its affiliates. All rights reserved.
PI-991704-AC